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Abstract: The nine papers selected for the “best of the month” cover
a broad range of topics including adjuvant therapy, targeted therapy
with epidermal growth factor or vascular endothelial growth factor
inhibitors, surgical approaches to lung cancer, and use of genomic
profiles.
Key Words: NSCLC, Lung cancer, Best papers.
(J Thorac Oncol. 2010;5: 1305–1307)
1. LONG TERM FOLLOW-UP DATA FROM
NON-SMALL CELL LUNG CANCER ADJUVANT
CHEMOTHERAPY TRIALS
Mixed Message!
Administration of postoperative chemotherapy for pa-
tients with resected non-small cell lung cancer (NSCLC) has
been in vogue only for the past few years and driven largely
by three recent prospective studies.1–3 Long-term follow-up
data from these adjuvant therapy studies are of great interest
to the lung cancer community. It is quite reassuring that even
after a median follow-up of 9.3 months, the JBR-10 study4
continues to show a persistent 5-year survival benefit for
adjuvant chemotherapy compared with observation (67 ver-
sus 56%). However, this survival benefit was restricted to
patients with stage II. The updated International Adjuvant
Lung Cancer Trial,5 in contrast, showed a decreasing benefit
from adjuvant chemotherapy after the first 5 years of follow-
up, with the absolute benefit in 5-year overall survival (OS)
reduced from 5.4 to 3.9%, now no longer statistically signif-
icant. No survival benefit for adjuvant chemotherapy was
observed in either stage II (hazard ratio [HR]  0.92; 95%
confidence interval  0.73–1.15) or stage III disease (HR 
0.85; 95% confidence interval  0.72–1.01). Possible expla-
nations for this discrepancy after the first 5 years of follow-up
include use of older generation of chemotherapy agents such
as vindesine or etoposide, administration of postoperative
radiotherapy in a significant proportion of patients, and an
increased non-lung cancer–related mortality in the Interna-
tional Adjuvant Lung Cancer Trial.
2. CETUXIMAB IN NSCLC
….In Need of a Predicted Biomarker!
Two large phase III trials recently evaluated the use of
first-line cetuximab in combination with platinum-based che-
motherapy in patients with advanced stage NSCLC. In the
first-line erbitux (FLEX)6 trial was published in 2009 and
showed a significant improvement in survival for the combi-
nation of cisplatin, vinorelbine, and cetuximab compared
with the same chemotherapy alone. In the second trial, the
Bristol-Myers Squibb 099,7 676 patients were randomized to
receive a carboplatin and a taxanes, either paclitaxel or
docetaxel, with or without cetuximab. The primary endpoint,
progression-free survival (PFS) according to the independent
radiologic review committee was not met (4.40 months for
the cetuximab arm and 4.24 months for the chemotherapy
only arm). Among the secondary endpoints, cetuximab was
associated with a significant improvement in overall response
rate (25.7 versus 17.2%, p  0.006) but not in OS (9.69
versus 8.38 months, p  0.16). The only clinical factor
correlated with survival benefit in the cetuximab arm was the
presence of acneiform rash of any grade by day 21 (median
survival of 10.4 months versus 8.9 months in patients with
rash versus no rash). The correlative part of Bristol-Myers
Squibb 099 study was performed in tumor samples from 225
randomly assigned patients.8 None of the markers tested,
including K-Ras mutation status, epidermal growth factor
receptor (EGFR) mutation status, EGFR protein expression
by immunohistochemistry, and EGFR gene copy number by
fluorescent in situ hybridization, were predictive for response
to cetuximab. With two studies showing opposite results and
no valid predictive marker, it is quite unlikely that cetuximab
would be used widely in the treatment of metastatic NSCLC.
3. HYPERTENSION IN PATIENTS RECEIVING
BEVACIZUMAB
Poor Man’s Biomarker
Bevacizumab is associated with a variety of severe
toxicities including gastrointestinal perforation, bleeding,
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thrombosis, would healing complications, and heart failure.
Hypertension is a relatively common toxicity, with approxi-
mately 15% of the patients requiring antihypertensive ther-
apy. With the hypothesis that hypertension may indicate the
successful blockage of the vascular endothelial growth factor
pathway, a retrospective study9 was conducted on the patients
treated in the phase III trial ECOG 4599, which compared the
efficacy of carboplatin and paclitaxel with bevacizumab
(PCB) or paclitaxel with chemotherapy alone. Among the
741 eligible patients, there were no differences in baseline
blood pressure (BP) measurements between patients accord-
ing to the treatment arm. Hypertension, defined as BP more
than 150/100 mmHg at baseline or at the end of cycle 1 or an
increase more than 20 mmHg between day 1 and 21, was
associated with a significant improvement in OS among
patients treated with PCB (15.9 versus 11.5 months). How-
ever, this difference in OS was not seen in patients treated
with chemotherapy alone. The survival benefit for patients
treated with PCB who developed high BP by the end of cycle
1 remained significant in a multivariate Cox model adjusting
for performance status, age, histology, sex, weight loss, and
metastatic pattern (HR  0.68, p  0.001). Survival benefit
for PCB remained significant compared with paclitaxel with
chemotherapy alone, even in patients who did not develop
high BP. Therefore, although hypertension during bevaci-
zumab treatment may require intervention to prevent cardio-
vascular complications, this toxicity may be viewed as an
equivalent to the skin rash in patients treated with EGFR
inhibitors, an inconvenience that may be beneficial.
4. BEVACIZUMAB IN PATIENTS WITH CENTRAL
NERVOUS SYSTEM METASTASES
Acceptable Risk
Since the initial report of a patient with hepatocellular
carcinoma who died of cerebral bleeding from a previously
undiagnosed brain metastasis during a phase I trial, patients
with central nervous system metastases have been excluded
from bevacizumab trials. In a recent study, Besse et al.10
evaluated the risk of cerebral hemorrhage in patients enrolled
in 13 randomized clinical trials, two single-arm safety trials,
and two prospective studies including patients with treated
brain metastases. Among the 8443 patients enrolled in the
randomized trials for NSCLC, breast cancer, pancreatic can-
cer, and colon cancer, there were 187 patients (2.2%) with
brain metastases, including 91 in patients treated with bev-
acizumab and 96 in patients receiving the control chemother-
apy. The rate of cerebral hemorrhage in this population was
3.3% in the bevacizumab arms and 1.0% in the control
groups. The incidence of cerebral hemorrhage in the two
open-label, single-arm studies, Safety of Avastin in Lung
(SAiL) (squamous cell lung cancer) and ATHENA (breast
cancer), which excluded patients with brain metastases at
presentation, was 0.9% (3 of 321 patients). Among 131
evaluable patients with NSCLC known treated brain metas-
tases and enrolled in the two prospective studies (PASSPORT
and ATLAS), one patient (0.8%) developed cerebral hemor-
rhage. Despite the limitations of a retrospective analysis
comparing selected populations across trials, bevacizumab
does not seem to be associated with a disproportional increase
in the risk of bleeding in patients with solid tumors and brain
metastases.
5. GEFITINIB VERSUS CHEMOTHERAPY IN
PATIENTS WITH EGFR TK MUTATED NSCLC
Ideal Drug for Patients with EGFR TK Mutated
NSCLC
In the landmark Iressa Pan-Asia Study (IPASS) study,
Mok et al.11 reported a significant improvement in the PFS for
gefitinib compared with chemotherapy with carboplatin and
paclitaxel in the subset of patients with lung adenocarcinoma
and EGFR mutation, while chemotherapy was superior in
those without the mutation. The West Japan Thoracic Oncol-
ogy Group (WJTOG) 340512 was a randomized multicenter
phase III trial comparing gefitinib versus cisplatin plus do-
cetaxel in patients with previously untreated advanced
NSCLC. Unlike the IPASS study, only patients with the
EGFR TK mutations were enrolled in this study. Among the
172 equally distributed patients included in the survival
analysis, the PFS was significantly longer in patients treated
with gefitinib (9.2 versus 6.3 months, p  0.0001). There
were no differences in survival according to the mutation type
(exon 19 deletions or L858R). The West Japan Thoracic
Oncology Group 3405 supports the results of the subset
analysis of survival from the IPASS based on EGFR mutation
and provided stronger support for the use of first-line gefitinib
in this selected patient population.
6. THORACOSCOPIC LOBECTOMY ON THE
RISE
Is Video-Assisted Thoracoscopic Surgery
Becoming More Popular?
There have been multiple reports showing that video-
assisted thoracoscopic surgery (VATS) is associated with
fewer postoperative complications compared with open tho-
racotomy. Because there are no randomized phase III trials
comparing the two approaches, Subroto et al.13 searched the
Society of Thoracic Surgeons General Thoracic Database
from 2002 to 2007 to allow a more comprehensive evalua-
tion. From an initial cohort of 6323 patients, 1281 patients in
each group were selected through propensity matching. Dur-
ing the study period, the percentage of patients undergoing
VATS increased from 10 to 27%. Although there were no
differences in operative mortality between the two groups,
the percentage of patients who had no surgical complications
in patients treated with VATS or open lobectomy were 73.8
and 65.3%, respectively (p  0.001). VATS was specifically
associated with a significantly lower incidence of arrhythmias
(7.3 versus 11.5%), pulmonary complications (7.5 versus
12.1%), and shorter length of stay (4 versus 6 days). This
database study provided further evidence that VATS is asso-
ciated with a lower incidence of complications, and its use
has steadily increased during the past 6 years.
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7. IS THERE A REASON FOR THE IMPROVED
OUTCOMES FOR NSCLC ACCORDING TO AGE
AND SEX?
A Genomic Look at the Demographic Variables
Despite clinical evidence for improved survival in pa-
tients with younger age and female gender, there is limited
information on the biologic differences that could explain this
variability in outcome. Mostertz et al.14 evaluated 787
NSCLC patient tumor samples, with corresponding clinical
data from four independent data sets. Patients with stages I to
IIIA were subdivided into four different subgroups according
to age and gender into younger than 70 years, 70 years or
older, men, and women. The relapse-free survival was sig-
nificantly better in younger patients (p  0.006) and women
(p  0.008). In both age groups and genders, there was a
significant survival difference between the high-risk and
low-risk clusters. Younger patients with high-risk for relapse
had increased probability of activation of the Src and TNF
gene signatures compared with the low-risk counterpart,
whereas older patients in the high-risk category had increased
activation of gene signatures for wound healing and invasive-
ness. Although men had an increased probability of activation
in the chromosomal instability, epigenetic stem cell, invasive-
ness, and Myc and wound healing pathways, the E2F1 path-
way was most commonly activated in women. Pathways
activated more commonly in high-risk women included in-
vasiveness and STAT3, whereas high-risk men had increased
activation of STAT3, TNF, wound healing, and EGFR. Al-
though these findings still require validation, this study rep-
resents a step forward in the understanding of biologic dif-
ferences among demographic variables, with likely
implications for individualized therapy.
REFERENCES
1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs.
observation in resected non-small-cell lung cancer. N Engl J Med
2005;352:2589–2597.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell lung
cancer. N Engl J Med 2004;350:351–360.
3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected stage
IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International
Trialist Association [ANITA]): a randomized controlled trial. Lancet
Oncol 2006;7:719–727.
4. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of
vinorelbine plus cisplatin compared to observation in completely re-
sected stage IB and II non-small-cell lung cancer: updated survival
analysis of JBR-10. J Clin Oncol 2010;28:29–34.
5. Arriagada R, Dunant A, Pignon J-P, et al. Long-term results of the inter-
national adjuvant lung cancer trial evaluating adjuvant cisplatin-based che-
motherapy in resected lung cancer. J Clin Oncol 2010;28:35–42.
6. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in
patients with advanced non-small-cell lung cancer (FLEX): an open-
label randomized phase III trial. Lancet 2009;373:1525–1531.
7. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxanes/
carboplatin chemotherapy in advanced non-small-cell lung cancer: re-
sults of the randomized multicenter phase III trial BMS099. J Clin Oncol
2010;28:911–917.
8. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential
predictive markers of cetuximab benefit in BMS099, a phase III study of
cetuximab and first-line taxanes/carboplatin in advanced non-small-cell
lung cancer. J Clin Oncol 2010;28:918–927.
9. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of ad-
vanced non-small-cell lung cancer patients experiencing hypertension
during treatment with bevacizumab in combination with carboplatin and
paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949–954.
10. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with
central nervous system metastases. Clin Cancer Res 2010;16:269–278.
11. Mok TS, Wu-Y-L, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in lung adenocarcinoma. N Engl J Med 2009;361:947–957.
12. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring muta-
tions of the epidermal growth factor receptor (WJTOG3405): an open
label, randomized phase 3 trial. Lancet Oncol 2010;11:121–128.
13. Subroto P, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is
associated with lower morbidity than open lobectomy: a propensity-
matched analysis from the STS database. J Thorac Cardiovasc Surg
2010;139:366–378.
14. Mostertz W, Stevenson M, Acharya C, et al. Age- and sex-specific genomic
profiles in non-small cell lung cancer. JAMA 2010;303:535–543.
Journal of Thoracic Oncology • Volume 5, Number 8, August 2010 Best of the Month
Copyright © 2010 by the International Association for the Study of Lung Cancer 1307
